This pilot study examined prospectively blood serum concentrations of fluvoxamine,
side effects and therapeutic response after a fixed dosage of 100 mg fluvoxamine/day
for 14 days. Twenty male and female patients who met the DSM-IV criteria of a major
depression received 50 mg fluvoxamine b.i.d. for two weeks. On days 7 and 14 side
effects and therapeutic response were registered and serum concentrations of fluvoxamine
were determined. A Receiver Operating Characteristic (ROC) curve was constructed to
determine a possible relationship between serum concentrations and clinical effects.
The serum concentrations of fluvoxamine were highly variable, even when dosages were
corrected for body weight, ranging between 23 to 227 μg/l. No relationship between
serum concentrations and side effects was detectable. On the other hand, ROC analysis,
conducted on day 14, revealed a significant upper concentration threshold of 85 μg/l
(p < 0.01) with no responder above this threshold. The results of this pilot study
should be regarded as a hint at the possible therapeutic benefits of lower fluvoxamine
serum concentrations by means of lower fluvoxamine dosages. Furthermore, this indicates
for the first time that therapeutic drug monitoring might be useful for patients under
antidepressant therapy with fluvoxamine.